drugset / Trial / NCT04149171

Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage

NCT04149171

Phase 3 Completed 30 enrolled Cristina Martinez
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Study Design: Single-center, not-randomized, open-label, two-arms controlled pilot clinical trial. Health Condition: Patients with severe trauma with a need for transfusion and categorized as priority 0 or 1 according to the Catalan Health Service (CatSalut) Polytrauma Code (PPT)

Timeline

Start
2018-09-26
Primary completion
2020-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fibrinogen Concentrate Human Protein / enzyme biologic
Comparator red blood cells Unknown
Comparator Tranexamic Acid Small molecule

Indications

No indication recorded.